SIGA Tech logo

SIGA Tech

Stock
Stock
Ticker: SIGA
SIGA

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

SIGA Tech has so far distributed $0.60 in 2026. The next dividend will be paid on 23.04.2027


$0.55

CHART BY

Frequently asked questions

The market capitalization of SIGA Tech is $229.92M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
SIGA Tech's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.0396. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover SIGA Tech's stock, with a consensus target price of $11.57. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, SIGA Tech reported a revenue of $53.66M.
SIGA Tech's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$10.55M. EBITDA measures the company's overall financial performance.
SIGA Tech has a free cash flow of -$20.50M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
SIGA Tech employs approximately 49 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of SIGA Tech is 41.08M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$229.92M
EPS (TTM) 
-$0.0396
Free Float 
41.08M
Revenue (TTM) 
$53.66M
EBITDA (TTM) 
-$10.55M
Free Cashflow (TTM) 
-$20.50M

Pricing

52W span
$2.835$9.43

Analyst Ratings

The price target is $11.57 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Employees
49
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
SIGA
Fundamentals & EOD data from FactSet
Join the conversation